Skip to content

    Research Use Only

    This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide

    Cerebrolysin

    Nootropic PeptideClinical

    Also known as: Cerebrolysin, Cere, EVER NEURO 215, Cerebrolyzin

    Cerebrolysin is a porcine brain-derived peptide complex developed by EVER Neuro Pharma (Austria) — a low-molecular-weight neurotrophic preparation containing a mixture of free amino acids and bioactive peptides extracted from purified pig brain proteins. Used clinically in 50+ countries (notably Russia, Eastern Europe, China, Mexico) for stroke recovery, traumatic brain injury, vascular dementia, and Alzheimer's disease. In the United States, Cerebrolysin is not FDA-approved and is sold as a research-only peptide.

    Half-Life: ~2-4 hours (multi-component peptide mix)MW: Not a single molecule. Cerebrolysin is a standardized concentrate (215.2 mg/mL) of free amino acids plus low-molecular-weight neuropeptides (below ~10 kDa), produced by controlled enzymatic digestion of purified porcine (pig) brain proteins.85 PubMed Studies
    Last reviewed:

    Overview

    At A Glance

    Mechanism

    Mechanism of action — pharmacological summary:

    Half-Life
    ~2-4 hours (multi-component peptide mix)
    Dosing
    Once daily
    Potential Benefits
    Improved cognition and global clinical function in mild-to-moderate Alzheimer's disease across six double-blind RCTs of 30 mL/day Cerebrolysin, with a placebo-comparable safety profile (PMID: 25832905)Modest gains in cognition (MMSE and ADAS-cog+) and global function in mild-to-moderate vascular dementia, though the Cochrane evidence is rated very low quality (PMID: 31710397)Small-to-medium improvement in functional and neuropsychological recovery after moderate-to-severe traumatic brain injury in the CAPTAIN trial program, statistically significant at days 30 and 90 (PMID: 33620612)Add-on use after acute ischemic stroke has been studied extensively, but Cochrane analysis of 7 RCTs found no clear benefit on death or dependency and a possible rise in non-fatal serious adverse events at 30 mL/day (PMID: 37818733)A 2021 systematic review and meta-analysis of animal-derived nootropics found a real but modest pro-cognitive effect for Cerebrolysin (PMID: 36324709)
    Safety Notes
    Common
    Mild injection site reaction

    Mechanism of Action

    Mechanism of action — pharmacological summary:

    • BDNF + NGF mimetic activity — the peptide complex contains fragments that mimic brain-derived neurotrophic factor and nerve growth factor, supporting neuronal survival
    • Anti-apoptotic — reduces neuronal death in models of ischemia, hypoxia, and excitotoxicity
    • Anti-inflammatory — suppresses microglial activation post-injury
    • Synaptic plasticity — increases long-term potentiation in hippocampal slices
    • Neurogenesis support — increases proliferation of neural stem cells in subventricular zone (rodent models)
    • Cholinergic enhancement — modulates acetylcholine pathways relevant to learning and memory

    Overview

    Cerebrolysin is a porcine brain-derived peptide complex developed by EVER Neuro Pharma (Austria) — a low-molecular-weight neurotrophic preparation containing a mixture of free amino acids and bioactive peptides extracted from purified pig brain proteins. Used clinically in 50+ countries (notably Russia, Eastern Europe, China, Mexico) for stroke recovery, traumatic brain injury, vascular dementia, and Alzheimer's disease.

    In the United States, Cerebrolysin is not FDA-approved and is sold as a research-only peptide. The published clinical literature is substantial: multiple Cochrane meta-analyses cover its use in acute ischemic stroke, dementia, and TBI rehabilitation, with mostly positive — though heterogeneous — outcomes.

    Mechanism is best characterized as BDNF/NGF-mimetic + neuroprotective rather than a single targeted drug action. The peptide complex appears to mimic endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity, and regeneration in injured tissue.

    Chemical Information

    IUPAC Name

    Not yet available

    CAS Number

    Not yet available

    Molecular Formula

    Not yet available

    Molecular Mass

    Not a single molecule. Cerebrolysin is a standardized concentrate (215.2 mg/mL) of free amino acids plus low-molecular-weight neuropeptides (below ~10 kDa), produced by controlled enzymatic digestion of purified porcine (pig) brain proteins.

    Amino Acid Sequence

    Not applicable - Cerebrolysin is a mixture of many peptides and free amino acids, not a single sequenced peptide, so it has no one defined amino-acid sequence.

    Dosing & Protocols

    Unlock Dosing Protocols

    Free account gets you:

    • View beginner, intermediate & advanced protocols
    • See weight-based dosing calculations
    • Access cycle length & frequency data

    2,800+ researchers already in

    Research

    Unlock Research Data

    Free account gets you:

    • Browse PubMed study summaries
    • See clinical trial phases & results
    • Access mechanism of action details

    2,800+ researchers already in

    Interactions

    Interaction Matrix

    Contraindications

    Do not use in: epilepsy or status epilepticus (may lower the seizure threshold), severe renal impairment, or known hypersensitivity to Cerebrolysin or any of its components. Avoid during pregnancy and breastfeeding (insufficient safety data). Give slowly and cautiously; the manufacturer's label warns against mixing it in the same infusion with balanced amino-acid solutions and against combining it with antidepressants or MAO inhibitors without medical supervision. Research use only in the US - not intended for human self-administration.

    Research Disclaimer

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    No listings found for Cerebrolysin.

    Get Cerebrolysin Price Drop Alerts

    Set a target price and we'll notify you when any vendor drops below it.

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Cerebrolysin.

    Related Compounds

    View All

    Adalank

    Nootropic PeptidePreclinical / Research compound

    Adalank is a hybrid research peptide combining structural elements of Adamax (the adamantyl-modified Semax analog) and Selank (the anxiolytic Pro-Gly-Pro tuftsin analog).

    t½ The commonly cited ~72-hour "functional duration" is an unverified community/vendor claim, not a measured value - no pharmacokinetic study of Adalank has ever been run. The figure is extrapolated from parent Adamax marketing claims. Actual serum half-life is unknown; there is no published PK data. 200-1200 mcg per dose (intranasal or subcutaneous), 1-2x daily
    PreclinicalView Profile

    Adamax

    Nootropic PeptidePreclinical / Research compound

    Adamax is a synthetic nonapeptide (Ac-MEHFPGPAG-NH2) classified as a designer analog of Semax.

    t½ No pharmacokinetic data. Community reports describe a subjectively long duration of effect (~2-3 days), supporting every-other-day or 3x/week dosing; serum half-life not characterized. 500-2000 mcg subcutaneous (community research dosing)
    PreclinicalView Profile

    Cortexin

    Nootropic PeptideMarketed in Russia/CIS (Geropharm); human clinical use with limited-quality evidence (small, mostly Russian-language studies; no Western RCT; not FDA/EMA approved)

    Cortexin is a purified peptide preparation extracted from cattle and pig cerebral cortex tissue — a low-molecular-weight neuropeptide complex used clinically in Russia and Eastern Europe for cognitive impairment, post-stroke recovery, encephalopathy, attention disorders, and pediatric developmental conditions. Like Cerebrolysin, Cortexin is positioned as a broad-spectrum neurotrophic preparation supplying bioactive peptides that mimic endogenous neurotrophic factors.

    t½ ~2-3 hours (estimated from analog peptide preparations)
    18 studiesView Profile

    NA-Semax

    Nootropic PeptidePreclinical

    NA-Semax is the N-acetyl-l-aspartyl variant of Semax — the original ACTH(4-7) Pro-Gly-Pro analog developed at the Russian Academy of Sciences in the 1990s.

    t½ ~20-30 minutes (intranasal, estimated from analog data)
    3 studiesView Profile

    NA-Semax Amidate

    Nootropic PeptidePreclinical

    NA-Semax Amidate is the C-terminally amidated NA-Semax — the carboxylic acid at the peptide's C-terminus is replaced with an amide group (-NH2), which is reported to further extend metabolic half-life by resisting carboxypeptidase cleavage in addition to the aminopeptidase resistance the N-acetyl group already provides. The practical effect is a peptide with dosing-frequency use: where standard Semax often requires 3-4 daily doses to maintain effect, NA-Semax Amidate is reported (in vendor monographs and community usage) to maintain subjective effects on a 1-2x daily schedule.

    t½ ~30-45 minutes (estimated, longer than standard Semax)
    2 studiesView Profile

    P-21

    Nootropic PeptidePreclinical

    P-21 is a synthetic cyclic dipeptide — Cyclo(L-prolyl-glycine) — derived from the Selank/Semax C-terminal Pro-Gly-Pro motif.

    t½ Not formally characterized in published work. P021 has only been studied in rodents (oral/dietary and subcutaneous dosing); no human pharmacokinetic data exist.
    4 studiesView Profile

    View Full Dosage Guide →

    Protocols, calculator & safety for Cerebrolysin

    Research Score

    54

    85 PubMed studies

    Quality Indicators

    Data Completeness

    75%
    Description
    Mechanism of Action
    Chemical Data
    Dosing Protocols
    Safety Profile
    PubMed Studies
    Interactions
    Vendor Listings

    Research Credibility

    85PubMed studies

    Well-researched compound

    Quick Facts

    Half-Life

    ~2-4 hours (multi-component peptide mix)

    Molecular Weight

    Not a single molecule. Cerebrolysin is a standardized concentrate (215.2 mg/mL) of free amino acids plus low-molecular-weight neuropeptides (below ~10 kDa), produced by controlled enzymatic digestion of purified porcine (pig) brain proteins.

    Trial Phase

    Clinical

    Safety Profile

    Moderate Risk

    Common Side Effects

    • Mild injection site reaction

    Stop Use If

    • Pregnancy/lactation
    • Severe renal impairment
    • Status epilepticus
    • Known peptide allergy

    Research Disclaimer

    This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

    Frequently Asked Questions

    Is Cerebrolysin FDA-approved?

    No. In the US it is sold only as a research chemical (research use only) and is not approved for human use. It is an approved prescription neurotrophic drug in roughly 50 countries across Europe, Asia, Russia, and Latin America.

    What is Cerebrolysin actually made of?

    It is not a single peptide. It is a standardized concentrate (215.2 mg/mL) of free amino acids and low-molecular-weight neuropeptides produced by enzymatically breaking down purified porcine (pig) brain proteins.

    Does the science actually support it?

    The honest answer is modest and uncertain. Hundreds of patients have been studied in RCTs and Cochrane reviews for stroke, vascular dementia, Alzheimer's, and TBI. Some show real benefits, but the certainty is generally low and the effect sizes are small (PMID: 31710397; PMID: 37818733).

    IM or IV - how is it given?

    Route depends on volume. Up to 5 mL can be injected IM; 10 mL should go in as a slow IV injection; and 10-50 mL doses are diluted in saline and infused slowly. Always give it slowly to avoid a transient feeling of heat or flushing.

    Who should avoid it?

    Anyone with epilepsy or status epilepticus, severe kidney impairment, or a known allergy to it, plus pregnant or breastfeeding women. Use caution alongside antidepressants or MAO inhibitors.

    Research Tools

    Related Compounds

    View All

    Adalank

    Nootropic PeptidePreclinical / Research compound

    Adalank is a hybrid research peptide combining structural elements of Adamax (the adamantyl-modified Semax analog) and Selank (the anxiolytic Pro-Gly-Pro tuftsin analog).

    t½ The commonly cited ~72-hour "functional duration" is an unverified community/vendor claim, not a measured value - no pharmacokinetic study of Adalank has ever been run. The figure is extrapolated from parent Adamax marketing claims. Actual serum half-life is unknown; there is no published PK data. 200-1200 mcg per dose (intranasal or subcutaneous), 1-2x daily
    PreclinicalView Profile

    Adamax

    Nootropic PeptidePreclinical / Research compound

    Adamax is a synthetic nonapeptide (Ac-MEHFPGPAG-NH2) classified as a designer analog of Semax.

    t½ No pharmacokinetic data. Community reports describe a subjectively long duration of effect (~2-3 days), supporting every-other-day or 3x/week dosing; serum half-life not characterized. 500-2000 mcg subcutaneous (community research dosing)
    PreclinicalView Profile

    Cortexin

    Nootropic PeptideMarketed in Russia/CIS (Geropharm); human clinical use with limited-quality evidence (small, mostly Russian-language studies; no Western RCT; not FDA/EMA approved)

    Cortexin is a purified peptide preparation extracted from cattle and pig cerebral cortex tissue — a low-molecular-weight neuropeptide complex used clinically in Russia and Eastern Europe for cognitive impairment, post-stroke recovery, encephalopathy, attention disorders, and pediatric developmental conditions. Like Cerebrolysin, Cortexin is positioned as a broad-spectrum neurotrophic preparation supplying bioactive peptides that mimic endogenous neurotrophic factors.

    t½ ~2-3 hours (estimated from analog peptide preparations)
    18 studiesView Profile

    NA-Semax

    Nootropic PeptidePreclinical

    NA-Semax is the N-acetyl-l-aspartyl variant of Semax — the original ACTH(4-7) Pro-Gly-Pro analog developed at the Russian Academy of Sciences in the 1990s.

    t½ ~20-30 minutes (intranasal, estimated from analog data)
    3 studiesView Profile

    NA-Semax Amidate

    Nootropic PeptidePreclinical

    NA-Semax Amidate is the C-terminally amidated NA-Semax — the carboxylic acid at the peptide's C-terminus is replaced with an amide group (-NH2), which is reported to further extend metabolic half-life by resisting carboxypeptidase cleavage in addition to the aminopeptidase resistance the N-acetyl group already provides. The practical effect is a peptide with dosing-frequency use: where standard Semax often requires 3-4 daily doses to maintain effect, NA-Semax Amidate is reported (in vendor monographs and community usage) to maintain subjective effects on a 1-2x daily schedule.

    t½ ~30-45 minutes (estimated, longer than standard Semax)
    2 studiesView Profile

    P-21

    Nootropic PeptidePreclinical

    P-21 is a synthetic cyclic dipeptide — Cyclo(L-prolyl-glycine) — derived from the Selank/Semax C-terminal Pro-Gly-Pro motif.

    t½ Not formally characterized in published work. P021 has only been studied in rodents (oral/dietary and subcutaneous dosing); no human pharmacokinetic data exist.
    4 studiesView Profile

    Free 2026 Peptide Cheat Sheet — 50 pages, PDF

    Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.

    Download Free

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.